# Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

> **NCT02250170** · PHASE1 · COMPLETED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 47 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** OPB-111077

## Key facts

- **NCT ID:** NCT02250170
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-23
- **Primary completion:** 2019-03-08
- **Final completion:** 2019-03-08
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02250170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02250170, "Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02250170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*